January 18, 2021, in order to actively respond to the rising trend of gram-negative bacteria resistance and better solve the increasingly serious multi-drug resistant infection treatment challenges caused by carbapenem-resistant enterobacteriaceae (CRE), Pfizer China and Cepheid China formally signed a strategic cooperation agreement in Shanghai. Pfizer and Cepheid announced that they would integrate their respective superior resources to enhance the rapid diagnosis of drug-resistant infections in medical institutions. This strategic cooperation will open up a new pattern for the diagnosis and treatment of moderate to severe infections in China.

The strategic cooperation between the Pfizer and Cepheid will start from the following four dimensions: the standardization of laboratory testing of drug-resistant bacteria in medical institutions, the ability of clinicians and clinical microbiologists in medical institutions to diagnose and detect drug-resistant gram-negative bacteria, the diagnosis and treatment capacity of clinical microbiologists in drug-resistant bacteria, and improvement of the inspection process for the molecular diagnosis project of drug-resistant bacteria from third-party testing institutions. including the improvement of the inspection process, to help improve the diagnosis and treatment of drug-resistant bacteria infections in my country and further curb the rising trend of bacterial resistance. This cooperation is expected to improve the diagnosis and treatment of drug-resistant bacterial infections, and further curb the rising trend of bacterial resistance.

Yiqin Wang, Vice President of Marketing Pfizer China Medical, and General Manager of Cepheid China signed a strategic cooperation agreement. General Manager of Anti-infection Business, Pfizer China Medical Bei Yang, Chief Medical Officer of Cyper/Danaher Diagnostic Platform Yiwei Tang and other company leaders attended and witnessed the signing ceremony.